The Harrington Discovery Institute at University Hospitals in Cleveland has teamed with venture investor Advent Life Sciences to launch the Advent-Harrington Impact Fund, which is designed to “advance breakthrough discoveries into novel treatments for the benefit of patients and society.”
The new fund, structured alongside Advent Life Sciences Fund III, contributes to the $215 million close of Advent’s funds focused on areas of high unmet medical need, Harrington and Advent said in a news release on Thursday morning, Feb. 18. The specific size of the Advent-Harrington Impact Fund was not disclosed.
Click here to read the complete story.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Originally published February 18, 2021.